[Management of aspergillosis in immunocompromised patients. Recommendations of Lille University Hospital--4th version--November 2004].
Invasive aspergillosis is a severe complication in immunocompromised patients. The arrival of new antifungal agents motivated the redaction of guidelines, regularly updated, by a Lille University hospital multidisciplinary task force. These guidelines assess diagnostic and therapeutic issues. The main recommended diagnosis tool is the chest CT scan, ordered at the smallest suspicion and, also, measure of the blood and broncho alveolar lavage fluid galactomannan. Treatment guidelines assess prophylaxis, empirical and documented therapy. Primary prophylaxis is warranted in only two cases, pulmonary graft or stem cell transplant in patients with chronic GVH and receiving corticosteroids. Empirical therapy should use one of the available amphotericin B formulations, chosen according to the patient history. Caspofungin is another choice. Documented therapy, depending on presentation, can be a single drug or a combination. First line therapy for single drug is i.v. voriconazole. Lipid formulations of amphotericin B are another choice. A combination therapy can be used as a first line treatment, for multiple lesions, or as salvage therapy. It must include caspofungin, associated with liposomal amphotericin B or voriconazole. A tight cooperation with thoracic surgeons is recommended.
Alfandari
S
S
Service de réanimation et maladies infectieuses, centre hospitalier Dron, 59208 Tourcoing, France. alfandari@nordnet.fr
Leroy
O
O
de Botton
S
S
Yakoub-Agha
I
I
Durand-Joly
I
I
Leroy-Cotteau
A
A
Beaucaire
G
G
D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans; D016867:Immunocompromised Host; D016377:Organ Transplantation; D014057:Tomography, X-Ray Computed
D000935:Antifungal Agents; D000666:Amphotericin B